Reimagining Science for the AI Era. Listen to @beckypferdehirt CEO of Radial @AsteraInstitute discuss the $500M nonprofit seeking to create better conditions for AI in biology. Sponsors: @AlphaSenseInc Dash Bio. https://t.co/FBraq3no2Z
Biotech in the Balance: Saving a Strategic Industry in an Age of Public Distrust. Listen to @jmaxlevin discuss his new book on The Long Run. Sponsored by: @AlphaSenseInc & Dash Bio. https://t.co/M6IT7KMW6D
Orexin drugs for narcolepsy and more. Alkermes Chairman and CEO Richard Pops is the latest guest on The Long Run podcast. Sponsored by @AlphaSenseInc and Dash Bio. https://t.co/QgBtp52Fwb
Biotech IPO Scorecard: Avalyn Pharma joins the Class of 2026. Seaport Therapeutics and Hemab Therapeutics next in line. Read more on how the IPO Class of 2026 is doing on TR. https://t.co/fWLFMN92NS
Small Molecule Synthesis Made Faster: Martin Burke is the latest guest on The Long Run. Sponsored by @AlphaSenseInc and Dash Bio. https://t.co/CQeYz75rSv
PhaseV Steps Up for Young Cancer Researchers. New Major Sponsor of Timmerman Traverse for Damon Runyon Cancer Research. Next trip: Sierras, Aug. 2-5. https://t.co/Pzz68lWyEU
Two interesting cancer drug startups profiled this week in TR. San Diego-based Sidewinder Therapeutics https://t.co/DRFKsrm4wi and Cambridge, Mass.-based Stipple Bio. https://t.co/rSPQIE0TVg
Computation, Chemistry & Culture for Drug Discovery. Nimbus Therapeutics CEO Abbas Kazimi is the latest guest on The Long Run. Sponsored by: @AlphaSenseInc and Dash Bio. https://t.co/dohaavq6xQ